BACKGROUND: Drug-resistance testing plays a critical role in selection of optimal treatment regimens for HIV infected individuals. Laboratories performing testing must implement quality control measures including external quality assessment. OBJECTIVES: The ENVA7 Programme (2007) was organised by QCMD to assess the performance of laboratories testing for drug-resistance mutations in the HIV-1 Protease and Reverse Transcriptase genes. STUDY DESIGN: The ENVA7 panel consisted of 5 lyophilised plasma samples (HIV-1 subtypes B, C and F). The viruses harboured wild type or resistant genotypes at various positions of the PR and RT genes. All IAS-defined resistance-associated codons were scored in comparison to the consensus sequence for each sample using a scoring system developed to allow simple and standardised comparisons between laboratories and/or technologies. RESULTS: 111 laboratories from 44 countries participated of which 95 submitted 98 datasets. 36 datasets were generated using ViroSeq (Abbott), 27 using TruGene (Siemens) and 35 using in-house assays. CONCLUSIONS: All technologies successfully genotyped each of the panel samples, irrespective of the virus subtype. While the assays for genotypic HIV drug-resistance determination have evolved into reliable and technically capable procedures of generating high quality results, variation in the quality of results is still observed between laboratories.
BACKGROUND: Drug-resistance testing plays a critical role in selection of optimal treatment regimens for HIV infected individuals. Laboratories performing testing must implement quality control measures including external quality assessment. OBJECTIVES: The ENVA7 Programme (2007) was organised by QCMD to assess the performance of laboratories testing for drug-resistance mutations in the HIV-1 Protease and Reverse Transcriptase genes. STUDY DESIGN: The ENVA7 panel consisted of 5 lyophilised plasma samples (HIV-1 subtypes B, C and F). The viruses harboured wild type or resistant genotypes at various positions of the PR and RT genes. All IAS-defined resistance-associated codons were scored in comparison to the consensus sequence for each sample using a scoring system developed to allow simple and standardised comparisons between laboratories and/or technologies. RESULTS: 111 laboratories from 44 countries participated of which 95 submitted 98 datasets. 36 datasets were generated using ViroSeq (Abbott), 27 using TruGene (Siemens) and 35 using in-house assays. CONCLUSIONS: All technologies successfully genotyped each of the panel samples, irrespective of the virus subtype. While the assays for genotypic HIV drug-resistance determination have evolved into reliable and technically capable procedures of generating high quality results, variation in the quality of results is still observed between laboratories.
Authors: Jessica D Church; Wei Huang; Neil Parkin; Natalia Marlowe; Laura A Guay; Saad B Omer; Philippa Musoke; J Brooks Jackson; Susan H Eshleman Journal: AIDS Res Hum Retroviruses Date: 2009-07 Impact factor: 2.205
Authors: Denise Cf Souza; Maria Cecilia A Sucupira; Rodrigo M Brindeiro; José Carlos C Fernandez; Ester C Sabino; Lilian A Inocencio; Ricardo S Diaz Journal: J Int AIDS Soc Date: 2011-09-21 Impact factor: 5.396
Authors: Annika Karlsson; Per Björkman; Göran Bratt; Håkan Ekvall; Magnus Gisslén; Anders Sönnerborg; Mattias Mild; Jan Albert Journal: PLoS One Date: 2012-03-20 Impact factor: 3.240
Authors: Sally Land; Julian Zhou; Philip Cunningham; Annette H Sohn; Thida Singtoroj; David Katzenstein; Marita Mann; David Sayer; Rami Kantor Journal: J Int AIDS Soc Date: 2013-07-10 Impact factor: 5.396